Speech by the President of the Government at the presentation of the Lilly Foundation Research Awards.

Spain José Luis Rodríguez Zapatero · Prime Minister of Spain

25 May 2005 · Presentation of the Lilly Foundation Research Awards

Context
Zapatero addressed the Lilly Foundation Biomedical Research Awards ceremony in Madrid on 25 May 2005, reaffirming government commitments to science and innovation.
Main themes
Biomedical research, scientific advancement, innovation and technological development, research funding and awards, clinical research, National Health System, private sector support for science, knowledge and humanism, government commitments to science policy, immune system research, Spain's research capacity
Duration
~24 min
74th percentile
Words
2,925
74th percentile
Sentences
81
53rd percentile
Readability
21
5th percentile
Grade
19.2
97th percentile
Syntax
3.60
96th percentile
Vocabulary
2.15
38th percentile

Translated from Spanish

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 29%28%
  • Social 25%25%
  • Technological 19%19%
  • Ceremonial 14%14%
  • Institutional 13%12%
  • Geopolitical 1%1%
  • Environmental 0%0%
  • Not in focus 1%

81 sentences in 47 paragraphs

Thank you very much, Minister of Education and Science, Minister of Health, President of the Lilly Foundation, President of the Spanish National Research Council,

Some of you may remember that in March 2004, as has been mentioned here, just a few days before the general elections, I had the opportunity to present my proposals on research in this very place as a candidate for the Presidency of the Government. I cannot forget that day. It has been recalled on some occasions, and I have done so publicly; but I left this event very convinced that a political change was going to take place in Spain.

That was an act of hope; certainly, hope for me; and also of passion, of passion for knowledge that I saw in this room and in so many researchers who fill us with pride in this country, like those we heard just a moment ago.

That event was also filled with commitments to contribute to a more scientifically modern society, with more advanced means, to make possible more progress, a better-distributed well-being, with new answers to the problems of new times; of ambition for change, for culture, to make knowledge accessible to all citizens, and a country that would stand by science.

I also remember that at that event I was preceded in speaking by Professor Federico Mayor Zaragoza, who fortunately is with us today, and to whom I would like to extend a warm greeting from here.

Therefore, it is a pleasure for me to return to this house to reaffirm my conviction that our future is played out in the raw material of the field of knowledge, innovation, and technological development; in the moral substance of ethical reflection on the model of society in which we decide to live. These are the two great foundations that will build the world of the 21st century: scientific advancement and renewed humanism.

I also come to reaffirm all the commitments I made then, to confirm that some have begun to be implemented, to ensure that the path taken will continue throughout the entire Legislature, and also to acknowledge that others are somewhat behind and that we must commit to promoting them with greater vigor, although you well know that our research project is evaluated based on results over four years, and therefore, I refer to that, except with the permission of the opposition, which has, of course, every right to evaluate it every day.

The occasion that brings us together is the presentation of the Lilly Foundation Biomedical Research Awards for its 2004 call, which have been awarded to Doctors Melchor Álvarez de Mon and Francisco Sánchez Madrid; who, by the way, have demonstrated brilliance, passion for science, and a great sense of humor in this forum, which is also a very important element for a job well done.

After having listened attentively to their concise but fascinating interventions, I would dare to suggest to them, because they have made a presentation very much around the immune system as a fundamental element in facing progress, greater health, and greater well-being; I would dare to suggest that they open a line of research -- the President of the Council can help in that direction -- on the immune system of politicians, because I believe that, without a doubt, it would strengthen the possibilities of what their ambition and objective represent, and certainly also another line of research around temperament as a fundamental element for good results in research tasks, as in all tasks of life.

There is no doubt that the professional trajectory and achievements of these two brilliant Spanish researchers, as we have been able to appreciate in the intervention of the President of the Foundation, are a clear example of the research quality developed within the National Health System, in university hospitals, which not only speaks well of their personal excellence but also of our organizational capacity and potential.

Clinical research, as a complement and source of rigor for the healthcare activity of health professionals, is one of the best contributions that health systems can make to patients and, therefore, to society in general. As such a valuable contribution, it must be recognized and stimulated from within the system itself.

But here we also recognize the commitment of the private initiative, a good example of how it can stimulate the development of research with these awards granted by the Lilly Foundation since its creation in 2001. Its objective is to endorse and highlight a scientific trajectory of the utmost relevance, providing support for its continuity and that of the research team that shares it in a discipline of great social impact, in a decisive discipline for the future, such as biomedicine.

The advances that have occurred in biomedicine and health sciences in the last century have represented a true revolution in developed societies. The fight against diseases that traditionally decimated populations has been crowned with the success of an overwhelming percentage, which has resulted in an increase in life expectancy that has practically doubled the values of just a hundred years ago.

Moreover, the perspectives now opened by discoveries in genomics and cell biology foresee solutions to health problems that were previously unthinkable. The findings of scientists are occurring at a dizzying speed, reducing the most optimistic timeframes.

The decoding of the human genome was completed several years ahead of schedule, and just recently we have witnessed with some astonishment the presentation to the media of the results of research with stem cells from the South Korean scientist Woo Suk Hwang's team. These discoveries, although they must be received with caution, as the international scientific community has done, may allow, perhaps in the not-too-distant future, a deep understanding of certain diseases, enabling the application of therapies that can prevent, cure, or reduce their painful effects or sequelae.

In this context, I must highlight the role that the pharmaceutical industry has played as a driving force for biomedical research, among other scientific disciplines. We cannot forget that the widespread use of certain medications, such as antibiotics, has helped cure diseases, saving thousands and thousands of lives, or that others, like vaccines, have managed, through prevention, to eradicate pathologies that in the past were considered true plagues that periodically ravaged a significant part of society.

I cannot overlook the fact that even today some of those plagues ravage entire towns and communities in less developed countries. With them, we have a duty of solidarity that we must be able to fulfill to be worthy of our human condition.

In our societies, the prolongation of life and the changing and permanent needs of current societies undoubtedly confront us with new and exciting challenges. The aging of the population and the demand from citizens for services that maintain or increase their quality of life generate economic tensions within health systems that, if not addressed with sufficient effectiveness, may hinder the well-being situation we currently enjoy and that has required so many efforts from numerous generations.

Therefore, the efficient financing of the National Health System is one of the Government's priority objectives. As you all know, this will be one of the topics to be addressed -- a fundamental topic to be addressed -- at the upcoming Conference of Presidents of Autonomous Communities with the Government, which will be held before the summer holidays. For this, we are working with the utmost rigor, in collaboration with the Autonomous Communities, in order to provide our National Health System with medium-term financial stability capable of guaranteeing citizens a level of services in line with their health and well-being needs and demands.

In the overall context of health financing, pharmaceutical spending constitutes one of the chapters that has experienced the greatest increases in recent years, which has made it necessary to adopt measures aimed at its containment in line with the decisions that have been made in the countries around us. The financial sustainability of the system requires solutions, in which all agents must be committed, and this also includes the productive sectors, of which the pharmaceutical sector is a key component in a developed society like ours.

The pharmaceutical industry offers a high level of technological development, has one of the highest productivity rates among all economic sectors in Spain, and carries out one of the most important research activities among all industrial sectors, while also maintaining sustained spending on Research and Development. It also employs the largest number of researchers in its workforce, contributing significantly to the increase of private investment in Research, Development, and Technological Innovation in Spain.

We are aware that maintaining these activities requires a stable framework that allows for the identification and development of long-term projects, which can be part of the development strategies of pharmaceutical companies, so that the results of research materialize in new medications made available to patients and healthcare professionals.

In order to find solutions that respect the legitimate aspirations of the different actors, it is necessary to establish points of encounter and an intelligent and constructive dialogue, from which imaginative solutions can be addressed, with flexible approaches, that achieve the viability and sustainability of the healthcare system, along with the stability that the Government desires for a dynamic, innovative, and highly qualified sector, such as the pharmaceutical one.

In my speech, more than a year ago, I also made a commitment to this house -- you may have noticed that the President is from León -- with the Spanish National Research Council: the fundamental reference for research.

In the period that has elapsed since then, the Council has conducted a detailed analysis of the actions of its various centers, units, and institutes, with the aim of concluding in the development of strategic action plans that can be integrated into the definition of the general plan of the organization. These plans, which involve the entire scientific community, are subjected to international evaluation.

The Council has also addressed the design and implementation of a true electronic administration, a substantive element given that the Council is a multicampus organization. Likewise, it has actively participated in the commission established to study and propose state agencies, with special attention to the unique aspects of flexibility in management, objective-driven leadership, and results evaluation. The work is well advanced and should signify in the near future the necessary organizational change to make effective the budgetary effort that, of course, the Government, and especially the President, is willing to make with this organization.

With these better and more flexible instruments, the Council aims to enhance collaboration with Autonomous Communities, Universities, and hospitals, as well as to launch decisive actions for scientific dissemination for research and innovative purposes.

The Council has also addressed the negotiation and reached an agreement to resolve the pending salary homologation issues with the groups of university teaching staff.

I reiterate my conviction that today more than ever, the progress, well-being, and wealth of countries depend on research, science, education, and the application of new technologies. Therefore, because we wish for Spain to be a country that stands at the forefront among developed countries in research and development, the Government is making, and will increase, a significant effort to implement new policies that allow for raising the level of research, that allow for quickly improving the indicators related to R&D&I, and that allow for producing knowledge and fostering a culture of innovation in companies.

Among these measures, I would like to highlight, as it was in this very place where I made my commitment to that line of action, those aimed at promoting stable hiring of young researchers with recognized trajectories, incorporating through competitive bidding the doctors from the Ramón y Cajal Program and other doctors contracted in the public system, both here, in the Council, and in Universities and other public research organizations.

I would also like to emphasize that the Ministry of Education and Science has already made significant progress, and I hope it will see the light very soon, on a draft reform of the Statute of Interns to achieve their incorporation into Social Security and to achieve the so-called 2+2: two pre-doctoral years with Social Security affiliation and two subsequent years with employment contracts. In this way, we aim to design a demanding but attractive career for our youngest researchers, avoiding the current situation of precariousness and lack of expectations.

On the other hand, as you all know, the Economic Dynamization Plan, approved last March by the Government, constitutes one of the elements of the strategy for increasing employment and boosting productivity in our country. Among the priority lines of action of this Plan, the one dedicated to promoting Research, Development, and Innovation stands out.

The Government is aware that, through Research, Development, and Innovation, we build the safest path, perhaps the only safe path, to more solid economic growth, to the creation of higher quality jobs, and therefore, it is determined to invest more and better.

Investing more means fulfilling the commitment made to the scientific community and to Spanish society to increase the budget for R&D&I by 25 percent each year throughout the Legislature; and, in addition, to improve the evaluation of the various programs of the National R&D&I Plan through the implementation of the Comprehensive Monitoring and Evaluation System.

Investing better means directing public resources towards four strategic actions:

The first strategic line aims to facilitate the creation of technology-based companies by improving the conditions for venture capital investments and through the enhancement of participatory loans for small and medium-sized enterprises.

A second strategic line is aimed at promoting public-private collaboration through the creation of national strategic consortia for technological research, the so-called CENIT Program, where researchers from the public and private systems work together with long-term contractual collaboration agreements.

The third strategic line is directed at increasing the critical mass and research excellence, with a reduction of bureaucratic difficulties and an increase in financial stability.

Finally, the fourth strategic line is aimed at promoting innovation through the adoption of information and communication technologies by citizens, companies, and, of course, by the entire Administration. To this end, we will present the Convergence Plan with Europe for the Information Society 2006-2009 before the end of the year.

In this context, I want to emphasize that Research, plus Development, plus business Innovation, are fundamental to turning knowledge into innovation, facilitating sustainable growth and greater employment. In addition, to the profitability of the company that makes the investment in R&D&I, we must add that of other companies that benefit from its activity, thus increasing the social profitability of their investments. Hence, the Lisbon Agenda aims, in addition to achieving that total investment in R&D reaches 3 percent of Gross Domestic Product, to involve the private sector in this process, so that its contribution reaches two-thirds of the total national investment.

In short, and as it relates to the private sector, the economic policy measures and research promotion adopted by the Government seek to shape an economic environment that encourages private investment in physical, human, and technological capital, and that fosters entrepreneurial spirit.

I want to conclude my speech by reiterating my commitment and that of the Government I lead to Science, to the budgetary effort of a 25 percent increase—which this year, of course, will essentially be directed from Chapter 1 to Chapter 7—, to research and to innovation, because we understand that it is the best investment for the future. To fulfill that commitment, we are willing to engage in dialogue and to achieve the participation of all.

Professor Severo Ochoa, one of our most distinguished scientists, as you all know in this house—of whom we also celebrate the centenary of his birth this year—said that, in principle, research needs more heads than means. The heads are undoubtedly the only irreplaceable element. In the context of his research laboratory in a foreign university, probably well-equipped, it was a statement full of truth; but today, I would say that indeed heads are needed, but means are also required, more means. The pharmaceutical industry knows this need very well, as it needs to invest around seven hundred million euros and fifteen years to bring a drug to market. But in addition to heads and means, I would add one more thing: organization to coordinate all of this and thus achieve the best results.

Ladies and gentlemen,

As we all know, the world of science in Spain has excellent minds, and we have seen many of them here today. We also treasure a great passion for knowledge, even if it is only the passion that we have not been able to have for so long in our collective history. Providing the means and the organization is the challenge we face.

But I want to leave you with a reflection to conclude. In these last thirty years, this country has managed to be an example of democratic coexistence and tolerance; in these last thirty years, this country has achieved growth, economic development, and well-being that align us with the most advanced countries; and in these last thirty years, we have demonstrated that we know how to be in the world, to open ourselves to the world, and to have a voice in the world. If we want to cover a stage of the next thirty years while being at the forefront as a country in tolerance and progress, science and research are our path. I can assure you that this is my commitment, and of course, I ask you to hold me accountable for it every day.

Thank you very much.